HIGHLIGHTS
- who: Daniel Rayson and colleagues from the Division of Medical Oncology, Department of Medicine, Queen Elizabeth II Health Sciences Center, Halifax, NS B H , Department of Medical Oncology, University Health Network, Toronto, ON M G , have published the Article: Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain, in the Journal: (JOURNAL)
SUMMARY
Chemotherapy given before definitive surgery, referred to as neoadjuvant therapy (NAT), can down-stage large tumours and allows for earlier treatment administration for breast cancers with a high risk of systemic recurrence . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.